The medication containing the active ingredient daraxonrasib is considered a major advance in the treatment of pancreatic cancer. The NCT Heidelberg, represented by Christoph Springfeld and Maximilian Jenzer, also participated in the international study on this topic. Daraxonrasib was approved in the U.S. in August, and a positive recommendation for approval has since been issued for Europe. In Germany, the drug is not yet approved, and access to it is strictly regulated.

The ARD “tagesthemen” and RTL also reported on the study results and their significance for the treatment of pancreatic cancer. Experts from the NCT Heidelberg were interviewed for both reports.

ARD “tagesthemen”: Drug Offers Hope for Pancreatic Cancer

On October 15, ARD’s “tagesthemen” reported on the study’s results and the new treatment options that the active ingredient could offer. The segment highlights the importance of targeted therapy in cancer treatment. The segment also discusses the NCT Heidelberg’s involvement in the clinical trial.

Watch the segment in the ARD media library (in German)

RTL: New Drug Daraxonrasib from a Patient’s Perspective

The RTL report from September 14 follows a patient with pancreatic cancer and highlights the importance of new therapeutic approaches from the perspective of someone living with the disease. Christoph Springfeld explains how Daraxonrasib works and contextualizes the study results as well as current treatment options.

Watch the report on RTL (in German)

Further information on the study and the NCT Heidelberg’s involvement